Biomedical Engineering Reference
In-Depth Information
86. Sanguinetti MC (1990) Na+1-activated and ATP-sensitive K+ channels in the heart. Prog
Clin Biol Res 334:85-109
87. Bischoff U, Schmidt C, Netzer R et al (2000) Effects of fluoroquinolones on HERG currents.
Eur J Pharmacol 406:341-343
88. Kang J, Wang L, Chen XL et al (2001) Interactions of a series of fluoroquinolone
antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 59:122-126
89. von Moltke LL, Greenblatt DJ, Duan SX et al (1994) In vitro prediction of the terfenadine-
ketoconazole pharmacokinetic interaction. J Clin Pharmacol 34:1222-1227
90. Dumaine R, Roy ML, Brown AM (1998) Blockade of HERG and Kv1.5 by ketoconazole.
J Pharmacol Exp Ther 286:727-735
91. Krantz MJ, Rowan SB, Schmittner J et al (2007) Physician awareness of the cardiac effects
of methadone: results of a national survey. J Addict Dis 26:79-85
92. Weiss R, Mevissen M, Hauser DS et al (2002) Inhibition of human and pig ureter motility
in vitro and in vivo by the K(+) channel openers PKF 217-744b and nicorandil. J Pharmacol
Exp Ther 302:651-658
93. Katapadi K, Kostandy G, Katapadi M et al (1997) A review of erythromycin-induced
malignant tachyarrhythmia-torsade de pointes. A case report. Angiology 48:821-826
94. Antzelevitch C, Sun ZQ, Zhang ZQ et al (1996) Cellular and ionic mechanisms underlying
erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 28:
1836-1848
95. Rampe D, Murawsky MK (1997) Blockade of the human cardiac K+ channel Kv1.5 by the
antibiotic erythromycin. Naunyn Schmiedebergs Arch Pharmacol 355:743-750
96. Drici MD, Knollmann BC, Wang WX et al (1998) Cardiac actions of erythromycin:
influence of female sex. JAMA 280:1774-1776
97. Sekkarie MA (1997) Torsades de pointes in two chronic renal failure patients treated with
cisapride and clarithromycin. Am J Kidney Dis 30:437-439
98. Woywodt A, Grommas U, Buth W et al (2000) QT prolongation due to roxithromycin.
Postgrad Med J 76:651-653
99. Su Z, Martin R, Cox BF et al (2004) Mesoridazine: an open-channel blocker of human ether-
a-go-go-related gene K+ channel. J Mol Cell Cardiol 36:151-160
100. Eap CB, Crettol S, Rougier JS et al (2007) Stereoselective block of hERG channel by
(S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol
Ther 81(5):719-728
101. Maremmani I, Pacini M, Cesaroni C et al (2005) QTc interval prolongation in patients on
long-term methadone maintenance therapy. Eur Addict Res 11:44-49
102. Routhier DD, Katz KD, Brooks DE (2007) QTc prolongation and torsades de pointes
associated with methadone therapy. J Emerg Med 32:275-278
103. Chouabe C, Drici MD, Romey G et al (2000) Effects of calcium channel blockers on cloned
cardiac K+ channels IKr and IKs. Therapie 55:195-202
104. Chouabe C, Drici MD, Romey G et al (1998) HERG and KvLQT1/IsK, the cardiac K+
channels involved in long QT syndromes, are targets for calcium channel blockers. Mol
Pharmacol 54:695-703
105. Anson BD, Weaver JG, Ackerman MJ et al (2005) Blockade of HERG channels by HIV
protease inhibitors. Lancet 365:682-686
106. Drolet B, Rousseau G, Daleau P et al (2001) Pimozide (Orap) prolongs cardiac repolarization
by blocking the rapid component of the delayed rectifier potassium current in native cardiac
myocytes. J Cardiovasc Pharmacol Ther 6:255-260
107. Kongsamut S, Kang J, Chen XL et al (2002) A comparison of the receptor binding and
HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 450:37-41
108. Kang J, Wang L, Cai F et al (2000) High affinity blockade of the HERG cardiac K(+) channel
by the neuroleptic pimozide. Eur J Pharmacol 392:137-140
109. Cubeddu LX (2009) Iatrogenic QT abnormalities and fatal arrhythmias: mechanisms and
clinical significance. Curr Cardiol Rev 5:166-176
